Blastic plasmacytoid dendritic cell neoplasia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Blastic plasmacytoid dendritic cell neoplasia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tagraxofusp-and-venetoclax-for-adults-with-untreated-blastic-plasmacytoid-dendritic-cell-neoplasm/ Wed, 29 Apr 2026 15:05:02 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tagraxofusp-and-venetoclax-for-adults-with-untreated-blastic-plasmacytoid-dendritic-cell-neoplasm/ This clinical trial is focused on studying a rare type of blood cancer called Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The study will evaluate the effectiveness and safety of a combination of two treatments: tagraxofusp and venetoclax. Tagraxofusp is a medication that targets specific cells in the body, while venetoclax is a type of drug known as a BCL-2 inhibitor, which helps to kill cancer cells. The purpose of the study is to see how well these two medications work together in patients who have not received any previous treatment for BPDCN.

Participants in the study will receive both tagraxofusp and venetoclax over a period of time. Tagraxofusp is given as an infusion, which means it is delivered directly into the bloodstream through a vein, while venetoclax is taken orally as a tablet. The study will monitor how patients respond to the treatment combination, looking for signs of improvement in their condition. The trial will also assess the safety of the treatment, checking for any side effects that may occur.

The study aims to determine the rate of complete remission, which means the cancer is no longer detectable, or a significant reduction in cancer symptoms after three cycles of treatment. Researchers will also look at other outcomes, such as how long patients remain free from cancer progression and overall survival rates. This trial is an important step in finding more effective treatments for BPDCN and improving the quality of life for those affected by this rare cancer.

]]> Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN https://clinicaltrials.eu/trial/study-of-sar443579-infusion-for-adults-and-children-with-relapsed-or-refractory-acute-myeloid-leukemia-b-cell-acute-lymphoblastic-leukemia-hr-mds-or-bpdcn/ Wed, 29 Apr 2026 14:47:53 +0000 https://clinicaltrials.eu/trial/study-of-sar443579-infusion-for-adults-and-children-with-relapsed-or-refractory-acute-myeloid-leukemia-b-cell-acute-lymphoblastic-leukemia-hr-mds-or-bpdcn/ This clinical trial is focused on studying the effects of a new treatment called in individuals with certain types of blood cancers. These include , , , and . The treatment, , is administered through an intravenous infusion, which means it is given directly into the bloodstream through a vein.

The purpose of the study is to find the most suitable dose of that can be safely given to patients and to evaluate its effectiveness in treating these blood cancers. The study is divided into two parts. In the first part, the focus is on determining the best dose for both adults and children. In the second part, the study aims to assess how well the treatment works at the recommended dose. Participants will receive the treatment and be monitored for any side effects and improvements in their condition.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their cancer. The study will help researchers understand more about the potential benefits and risks of for treating these serious conditions. The information gathered from this trial could contribute to developing new treatment options for patients with these types of blood cancers.

]]>